Intravesical chemotherapy of superficial bladder tumors in a controlled trial with cis‐platinum versus Cis‐platinum plus hyaluronidase

Horn, Y.; Eidelman, A.; Walach, Natalio; Waron, M.; Barak, Frida

doi:10.1002/jso.2930280414

Cited by 13 publications

(2 citation statements)

References 15 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cisplatin is considered to be the most effective chemotherapeutic treatment for advanced bladder cancer, and it has been suggested as an efficient alternative treatment for nonmuscle invasive bladder cancer (NMIBC). , Horn et al showed the efficacy of cisplatin as a local agent for treatment of superficial bladder tumors . Hadaschik et al demonstrated that use of cisplatin as an intravesical agent significantly inhibits bladder tumor growth .…”

Section: Introductionmentioning

confidence: 99%

“…20,21 Horn et al showed the efficacy of cisplatin as a local agent for treatment of superficial bladder tumors. 22 Hadaschik et al demonstrated that use of cisplatin as an intravesical agent significantly inhibits bladder tumor growth. 23 particles was suggested by Huxford et al 24 and was demonstrated by functionalized PLGA/PEG nanoparticles to prostate cancer cells.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Biodegradable Controlled-Release Device for Localized Chemotherapeutic Treatment of Bladder Cancer

Kabha

Bukchin-Tihomirov

Shlomi

et al. 2021

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

Intravesical therapy for the treatment of superficial urinary bladder tumors is promising. However, it is also challenging, due to bladder contraction and relaxation and drug elimination via urination or dilution by urine production. We developed a biodegradable drug-eluting device positioned in the renal pelvis as an alternative strategy for bladder instillation. The urine drains from the renal pelvis into the ureter, collects the eluted drug, and transports it into the bladder. The combination of the renal pelvis and the bladder creates a two-compartment system. The drug is administered into the depot compartment, the renal pelvis, and is instantly and homogeneously distributed into the central compartment, the bladder. This results in an increase in its residence time and in gradual adsorption into the urothelium. The device is inserted through the ureter, followed by upset bulging after reaching the renal pelvis in order to guarantee fixation, while preventing urinary obstruction. The device is made of electrospun poly(lactic-co-glycolic acid) (PLGA) fibers that encapsulate a chemotherapeutic drug, cisplatin (1.17−2.34% w/w). Experimental studies of the stresses developed during the bulging and simulations of the urine flow interaction with the device demonstrated structural longevity and operational safety of the device. Sustained release of 94% of the device content was demonstrated after 1 week in vitro with a flow rate of 30 mL/h. We believe that the drug-eluted device may offer a significant advantage over existing therapies for treatment of nonmuscle invasive bladder cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Biodegradable Controlled-Release Device for Localized Chemotherapeutic Treatment of Bladder Cancer

Kabha

Bukchin-Tihomirov

Shlomi

et al. 2021

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

show abstract

Efficacy of intravesical mitomycin C in the treatment of superficial transitional cell carcinoma of the urinary bladder

Pavlotsky

Eidelman

Barak

et al. 1989

Journal of Surgical Oncology

Self Cite

View full text Add to dashboard Cite

We treated 47 patients with recurrent transitional cell carcinoma of the bladder with intravesical chemotherapy. Twenty milligrams of mitomycin C per treatment was introduced 7 days after transurethral resection (TUR) or diagnostic cystoscopy, and was repeated at 2-week intervals for five times followed again by cystoscopy. Two more similar courses were administered for a total of 36 weeks. Clinical data revealed no toxicity-related symptoms. Cystoscopic follow-up showed a gradual decline in the presence of tumor to a complete response rate of 87.1% at 36 weeks. Thirteen patients who were previously treatment failures with other drugs responded to mitomycin C.

show abstract

Long‐term follow‐up of patients with superficial transitional cell carcinoma of the urinary bladder treated by intravesical mitomycin C

Pavlotsky

Eidelman

Barak

et al. 1995

Journal of Surgical Oncology

Self Cite

View full text Add to dashboard Cite

Prophylactic intravesical chemotherapy (IVC) reduces recurrence rates of superficial transitional cell carcinoma (TCC) of the urinary bladder. The patient cohort existed of 86 individuals (stage TaN0M0 or T1N0M0) superficial carcinoma of various grades of malignancy. Following initial transuretheral resection or diagnostic cystoscopy, mitomycin C (MMC), 20 mg dissolved in 50 ml saline, was instilled intravesically by catheter over 1 hr at 2-week intervals, initially and then four more times followed by diagnostic cystoscopy (one course = 12 weeks). Two similar courses were administered thereafter for a total period of 36 weeks. For patients in remission, installations continued in monthly fractionations for 9 more months (cystoscopy every 3 months) and then at 2-month intervals for 12 more months (cystoscopy every 6 months). When cystoscopy revealed recurrence, IVC was repeated from the beginning. No symptoms of MMC-related toxicity were observed. Cystoscopic follow-up evaluations showed a complete response rate of 84% at 3 years and 81% at 5 years after initial therapy. Twenty-seven patients who had not responded to previous treatment with other drugs responded to MMC.

show abstract

Intravesical chemotherapy of superficial bladder tumors in a controlled trial with cis‐platinum versus Cis‐platinum plus hyaluronidase

Cited by 13 publications

References 15 publications

Biodegradable Controlled-Release Device for Localized Chemotherapeutic Treatment of Bladder Cancer

Biodegradable Controlled-Release Device for Localized Chemotherapeutic Treatment of Bladder Cancer

Efficacy of intravesical mitomycin C in the treatment of superficial transitional cell carcinoma of the urinary bladder

Long‐term follow‐up of patients with superficial transitional cell carcinoma of the urinary bladder treated by intravesical mitomycin C

Contact Info

Product

Resources

About